Zobrazeno 1 - 10
of 3 316
pro vyhledávání: ''
Autor:
Erik S.G. Stroes, Nick S. Nurmohamed
Publikováno v:
Netherlands Heart Journal
Nurmohamed, N S & Stroes, E S G 2022, ' Working towards full eradication of lipid-driven cardiovascular risk? ', Netherlands Heart Journal, vol. 30, no. 1, pp. 15-24 . https://doi.org/10.1007/s12471-021-01600-8
Nurmohamed, N S & Stroes, E S G 2022, ' Working towards full eradication of lipid-driven cardiovascular risk? ', Netherlands Heart Journal, vol. 30, no. 1, pp. 15-24 . https://doi.org/10.1007/s12471-021-01600-8
Lipid-driven cardiovascular disease (CVD) risk is caused by atherogenic apolipoprotein B (apoB) particles containing low-density lipoprotein cholesterol (LDL-C), triglycerides and lipoprotein(a) [Lp(a)] and resembles a large and modifiable proportion
Autor:
K. I. Dubatouka, I. E. Adzerikho, T. E. Vladimirskaya, V. E. Agabekov, I. L. Lutsik, N. Lugovska, E. S. Branovitskaya, E. A. Chernyavsky
Publikováno v:
Journal of Thrombosis and Thrombolysis. 53:313-320
The use of streptokinase (SK) in the clinic is limited by the lack of fibrin-specificity and the short half-life of the drug. We have developed a new dosage form of streptokinase (immunoliposome), which consists of "free" native streptokinase and "bo
Autor:
Jecko Thachil
Publikováno v:
Seminars in Thrombosis and Hemostasis. 48:240-243
Protamine is now well recognized as a key heparin neutralizing agent. However, protamine was discovered over a century ago, during experiments performed to uncover the secrets behind heritability. Although protamine was discovered as a highly charged
Autor:
Simon W. Lam, Mohamed Amar, Kathleen D. Faulkenberg, J. Bradley Williams, Antonio L. Perez, W.H. Wilson Tang
Publikováno v:
Journal of Cardiac Failure. 27:1053-1060
Background The role of oral vasodilators in the management of acute decompensated heart failure (ADHF) is not clearly defined. We evaluated the use of captopril vs hydralazine-isosorbide dinitrate (H-ISDN) in the transition from sodium nitroprusside
Autor:
Giuseppe Lippi, Maria Helena Santos de Oliveira, Ivan Szergyuk, Brandon Michael Henry, Justin L. Benoit, Stefanie W. Benoit, Emmanuel J. Favaloro
Publikováno v:
Journal of Thrombosis and Thrombolysis
Lipoprotein(a) (Lp(a)) is a prothrombotic and anti-fibrinolytic lipoprotein, whose role has not been clearly defined in the pathogenesis of coronavirus disease 2019 (COVID-19). In this prospective observational study, serum Lp(a) as well as outcomes
Publikováno v:
Vascular Health and Risk Management
Lipoprotein(a) forms a subfraction of the lipid profile and is characterized by the addition of apolipprotein(a) (apo(a)) to apoB100 derived particles. Its levels are mostly genetically determined inversely related to the number of protein domain (kr
Publikováno v:
Cardiovascular Toxicology. 21:936-946
Doxorubicin (DOX) is used as an anticancer drug despite its several side effects, especially its irreversible impacts on cardiotoxicity. Coenzyme Q10 (Q10) as a powerful antioxidant and lisinopril (LIS) as an angiotensin-converting enzyme inhibitor s
Publikováno v:
Cardiovascular Drugs and Therapy. 36:829-840
Ticagrelor and dapagliflozin can suppress the activation of the NOD-like receptor 3 (NLRP3)-inflammasome and activate AMP-activated protein kinase (AMPK). The anti-inflammatory effects of dapagliflozin has been shown to depend on AMPK activation. Dap
Autor:
Mary E. Keebler, Moses Demehin, Christopher M. Sciortino, Massimo Mangiola, Ed Horn, Roy Sriwattanakomen, Qingyong Xu, Adriana Zeevi, M. Shullo, Gavin Hickey
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:595-603
Background Allosensitization in heart transplant candidates is associated with longer transplant wait times and post-transplant complications. We summarize our experience with desensitization using carfilzomib , an irreversible proteasome inhibitor t
Autor:
Vivek Srivastava, Ioannis Akoumianakis, Keith M. Channon, George Krasopoulos, Elsa Mauricio Reus, Alexios S. Antonopoulos, Rana Sayeed, Murray Polkinghorne, Surawee Chuaiphichai, Nadia Akawi, Shakil Farid, Elena Sommariva, H Kondo, Christos P Kotanidis, Barbara Casadei, Evangelos Oikonomou, Cheerag Shirodaria, Ilaria Stadiotti, Maria Cristina Carena, Ileana Badi, Charalambos Antoniades
Publikováno v:
European Heart Journal
Aims Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an S